title: Other pharmacological treatments for motor complications and dyskinesias.
abstract: Controlling motor complications becomes increasingly difficult with disease progression. The "wearing-off" phenomenon is the most-common motor fluctuation. Wearing-off can be treated by dietary manipulation, shortening the dosing interval, substituting sustained-release levodopa, adding amantadine, or monoamine oxidase type B inhibitors, and other options, including catechol-O-methyltransferase inhibitors and the approved dopamine agonists addressed in another chapter. The rotigotine constant-delivery system is being developed to treat wearing-off symptoms. Istradefylline (KW-6002), an adenosine A(2A) receptor antagonist, has been studied for wearing-off and the results will be discussed. The on-off fluctuations can be treated with liquid levodopa and the rescue therapy of injectable apomorphine. Patients may also suffer from dyskinesias. Dyskinesias can be treated with small doses of liquefied levodopa-carbidopa, amantadine, and clozapine, an atypical neuroleptic.
authors.affiliation: Division of Movement Disorders, Department of Neurology, Columbia University, 710 West 168th Street, New York, NY 10032, USA. cw345@columbia.edu
authors.forename: Cheryl
authors.initials: C
authors.lastname: Waters
mesh_terms: D000547:Amantadine / Q000494:pharmacology / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology*; D005684:Gait / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy; D010507:Periodicity; D058915:Purinergic P1 Receptor Antagonists; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D058915:Purinergic P1 Receptor Antagonists; D011687:Purines; C111599:istradefylline; D012642:Selegiline; D007980:Levodopa; D000547:Amantadine; D008995:Monoamine Oxidase